PCSK9 Inhibitors for Large-Artery Stroke Recovery
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a cholesterol-lowering medication called evolocumab (a PCSK9 inhibitor) can help people recover better after a specific type of stroke caused by clogged arteries. The study checks if lowering cholesterol further than usual statins do improves stroke outcomes and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Recent acute ischemic stroke (within 72 hours) confirmed by imaging and diagnosed as large-artery atherosclerosis type
- Mild-to-moderate stroke severity (NIHSS score 4–20)
- No severe heart, liver, or kidney disease
- LDL cholesterol level of at least 1.8 mmol/L (about 70 mg/dL)
- Never taken a PCSK9 inhibitor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a PCSK9 inhibitor (a newer cholesterol-lowering medicine) to standard care helps people who had a stroke from a large artery blockage and had a clot-removal procedure. It may lower bad cholesterol further and reduce the risk of another stroke.
This trial tests whether giving a PCSK9 inhibitor (a type of cholesterol-lowering medicine) early after a stroke can improve recovery and lower 'bad' cholesterol. It is for people who have had a non-cardioembolic stroke (not from a heart problem) caused by hardening of the arteries.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This trial tests whether a cholesterol-lowering medication (PCSK9 inhibitor) can help prevent further strokes in people who have recently had a stroke or mini-stroke due to a narrowed artery in the brain. It is for adults 30 to 80 years old who meet specific health criteria.
This trial tests a smart computer tool that helps doctors manage your cholesterol treatment with Evolocumab (Repatha). If you have had a recent stroke or mini-stroke and are already taking this medicine, the tool may help you reach your LDL (bad cholesterol) goal faster.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.